Alcon buys Neurotech for USD 550 million: Berenberg backs Alcon stock

Published on 10/21/2026 at 10:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock costs EUR 60.45 on October 21, 2026, 0.65 percent above the Xetra close. Q3 results are due November 10, 2026.

Acquisition and earnings calendar

Alcon paid USD 550 million for Neurotech on October 20, 2026.
Alcon expects modest net sales growth and slight core diluted earnings per share dilution in 2027.
Alcon stock trades at EUR 60.45 at 10:38 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.65 percent above the Xetra close of October 20, 2026.

Bauhaus style graphic design poster in wide horizontal format. Geometric stylized eye centered, iris as concentric circles and radial lines in primary red, blue, yellow on cream white, heavy black outlines, flat bold shapes, no gradients — Alcon CH0432492467: Bauhaus Poster mit geometrischem Auge und Linse in den Primärfarben Rot und Blau, Illustration mit AI erstellt.

Alcon (CH0432492467) paid USD 550 million for Neurotech Pharmaceuticals on October 20, 2026, expanding its retina portfolio with ENCELTO, according to Alcon. A same-day report said Zonebourse that Berenberg maintained a Buy rating on Alcon.

Deal adds a retina platform

ENCELTO is the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a rare progressive retinal disease. Alcon said the therapy is available only in the United States and that additional contingent payments may depend on commercial milestones, according to Alcon.

What does the deal mean for 2027?

Alcon expects the acquisition to contribute modestly to net sales growth but to be slightly dilutive to core diluted earnings per share in 2027, with a positive earnings contribution after that period, the company said in its October 20, 2026 release. The transaction therefore adds a commercial platform before it becomes an earnings driver.

Three dated catalysts

On October 7, 2026, Barclays initiated coverage with an Equal Weight rating and a USD 70.00 price target, as listed by MarketScreener. On October 12, 2026, BTIG cut its target from USD 82.00 to USD 74.00 while keeping a Buy rating, according to Markets Insider.

On October 20, 2026, Alcon announced the USD 550 million Neurotech acquisition, making it the latest event in that sequence.

Next reporting date

Alcon is scheduled to report third-quarter 2026 results on November 10, 2026, according to MarketScreener. That date will provide the next test of product momentum and the cost of expanding the retina portfolio.

Price stays above the Xetra close

At Lang & Schwarz, Alcon stock was trading at EUR 60.45 on October 21, 2026 at 10:38 a.m. CEST, up 0.65 percent versus the Xetra close of October 20, 2026 at EUR 60.06. The primary listing is on SIX and NYSE, while the latest USD market capitalization was USD 32.8 billion as of October 20, 2026; the 52-week range was USD 61.84 to USD 87.64.

The further course of trading is shown by the continuously updated real-time quote of Alcon stock.